Organicell Regenerative Medicine Inc (OTCMKTS:BPSR) soared this morning on the back of positive results from the clinical trial of its COVID 19 medicine Zofin that took place in India.
BPSR shares as of 12:40 are trading at .179 up .13 for a gain of 266% on the day. Volume is 48 million shares crushing its 30-day average volume of 1.5 million shares a day. Trading opened at .08 and ran to a high of .19.
The trial was conducted on ten COVID 19 patients in India and was accomplished in collaboration with CWI India, the company’s partner in the country.
From the press release: “The explosive spread of COVID-19 in India, and the lack of treatment that is available to help these millions of people is quite alarming and tragic. We are hopeful that Zofin™ can continue to help these patients, and we will do everything we can to expedite this process,” said Albert Mitrani, CEO of Organicell.
The trial was conducted to see the effect of Zofin on patients suffering from moderate to severe symptoms of COVID 19. The first ten patients who had been treated with the product had all been hospitalized. However, after administering Zofin the patients recovered and were eventually discharged. It is a significant milestone for the company. The company is now aiming to expand the scope of the trial and enroll sixty-five patients for the purpose.